Cite
Brandes AA, Finocchiaro G, Zagonel V, et al. Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. Oncotarget. 2017;8(33):55575-55581doi: 10.18632/oncotarget.15735.
Brandes, A. A., Finocchiaro, G., Zagonel, V., Reni, M., Fabi, A., Caserta, C., Tosoni, A., Eoli, M., Lombardi, G., Clavarezza, M., Paccapelo, A., Bartolini, S., Cirillo, L., Agati, R., & Franceschi, E. (2017). Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. Oncotarget, 8(33), 55575-55581. https://doi.org/10.18632/oncotarget.15735
Brandes, Alba A, et al. "Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study." Oncotarget vol. 8,33 (2017): 55575-55581. doi: https://doi.org/10.18632/oncotarget.15735
Brandes AA, Finocchiaro G, Zagonel V, Reni M, Fabi A, Caserta C, Tosoni A, Eoli M, Lombardi G, Clavarezza M, Paccapelo A, Bartolini S, Cirillo L, Agati R, Franceschi E. Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. Oncotarget. 2017 Feb 25;8(33):55575-55581. doi: 10.18632/oncotarget.15735. eCollection 2017 Aug 15. PMID: 28903444; PMCID: PMC5589683.
Copy
Download .nbib